Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2018-10-25
Target enrollment:
Participant gender:
Summary
This pilot phase II trial studies how well erlotinib hydrochloride works in treating patients
with relapsed or refractory acute myeloid leukemia. Erlotinib hydrochloride may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Astellas Pharma Inc National Cancer Institute (NCI)